On August 14, 2024, Apollomics Inc., a clinical-stage biotechnology company, reported unaudited condensed consolidated interim financial statements for the first half of the year ending June 30, 2024. The company, which focuses on developing oncology therapies, also provided management's discussion and analysis (MD&A) of its financial condition and results of operations. Apollomics, listed on the Nasdaq Capital Market, follows home country governance practices in lieu of certain Nasdaq requirements. The company's financial results were disclosed in a press release and filed with the SEC, incorporating the information into the company's registration statements. Apollomics' pipeline includes nine product candidates across 11 programs, with a strategic focus on difficult-to-treat cancers. Recent events include a strategic shift in the clinical development...Show More

On August 14, 2024, Apollomics Inc., a clinical-stage biotechnology company, reported unaudited condensed consolidated interim financial statements for the first half of the year ending June 30, 2024. The company, which focuses on developing oncology therapies, also provided management's discussion and analysis (MD&A) of its financial condition and results of operations. Apollomics, listed on the Nasdaq Capital Market, follows home country governance practices in lieu of certain Nasdaq requirements. The company's financial results were disclosed in a press release and filed with the SEC, incorporating the information into the company's registration statements. Apollomics' pipeline includes nine product candidates across 11 programs, with a strategic focus on difficult-to-treat cancers. Recent events include a strategic shift in the clinical development of vebreltinib for NSCLC patients with Met Amplification and executive leadership changes. The company's financial performance for the first half of 2024 showed a net loss of $35.2 million, with research and development expenses amounting to $16.9 million and administrative expenses totaling $10.2 million. Apollomics believes its current cash reserves are sufficient for at least the next 12 months.